SNMMI meeting offers a special focus on radium-223 dichloride

05/21/2013 | MolecularImaging.net

A number of education sessions at this year's SNMMI Annual Meeting will focus on the newly approved radium-223 dichloride, a targeted radioisotope therapy for castrate-resistant prostate cancer, writes SNMMI Outreach Committee Co-chair Dr. Andrei Iagaru. "This is an exciting time for nuclear medicine as alpha radiation is not routinely used as a treatment. Preliminary results are encouraging and many [patient] and referring physician organizations have expressed interest in the new therapy," Iagaru writes.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations